{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:21Z","timestamp":1790286921419,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13400-5","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T03:15:26Z","timestamp":1736824526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed\/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0174-2906","authenticated-orcid":false,"given":"Fanqiao","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoyuan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"6","key":"13400_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1200\/JCO.23.01799","volume":"42","author":"KM Kelly","year":"2024","unstructured":"Kelly KM, Friedberg JW. Classic Hodgkin lymphoma in adolescents and young adults. J Clin Oncol. 2024;42(6):653\u201364.","journal-title":"J Clin Oncol"},{"key":"13400_CR2","doi-asserted-by":"publisher","first-page":"115073","DOI":"10.1016\/j.ejca.2024.115073","volume":"213","author":"C Rossi","year":"2024","unstructured":"Rossi C, Manson G, Marouf A, Cabannes-Hamy A, Nicolas-Virelizier E, Maerevoet M, Alcantara M, Molina L, Ceraulo A, Poiree M, et al. Classic Hodgkin lymphoma: the LYSA pragmatic guidelines. Eur J Cancer. 2024;213:115073.","journal-title":"Eur J Cancer"},{"issue":"4","key":"13400_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/jha2.784","volume":"4","author":"FG Keller","year":"2023","unstructured":"Keller FG, Kahl B, Friedberg JW. Current directions in the treatment of classical Hodgkin lymphoma. EJHaem. 2023;4(4):908\u201311.","journal-title":"EJHaem"},{"issue":"9","key":"13400_CR4","doi-asserted-by":"publisher","first-page":"10351","DOI":"10.1002\/cam4.5765","volume":"12","author":"C Zhang","year":"2023","unstructured":"Zhang C, Deng J, Xie Y, Mi L, Liu W, Wang X, Zhao L, Song Y, Zhu J. Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory\/relapsed classical Hodgkin lymphoma. Cancer Med. 2023;12(9):10351\u201362.","journal-title":"Cancer Med"},{"issue":"6","key":"13400_CR5","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.hoc.2014.08.011","volume":"28","author":"NM Reddy","year":"2014","unstructured":"Reddy NM, Perales MA. Stem cell transplantation in Hodgkin lymphoma. Hematol Oncol Clin North Am. 2014;28(6):1097\u2013112.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9980","key":"13400_CR6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853\u201362.","journal-title":"Lancet"},{"issue":"11","key":"13400_CR7","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s00228-023-03557-6","volume":"79","author":"J Arabloo","year":"2023","unstructured":"Arabloo J, Azari S, Gorji HA, Rezapour A, Alipour V, Ehsanzadeh SJ. Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review. Eur J Clin Pharmacol. 2023;79(11):1443\u201352.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"13400_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/ejh.14074","volume":"112","author":"M Ho","year":"2024","unstructured":"Ho M, Zanwar S, Paludo J. Chimeric antigen receptor T-cell therapy in hematologic malignancies: successes, challenges, and opportunities. Eur J Haematol. 2024;112(2):197\u2013210.","journal-title":"Eur J Haematol"},{"issue":"12","key":"13400_CR9","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/ajh.27470","volume":"99","author":"SM Ansell","year":"2024","unstructured":"Ansell SM. Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(12):2367\u201378.","journal-title":"Am J Hematol"},{"issue":"12","key":"13400_CR10","doi-asserted-by":"publisher","first-page":"e971","DOI":"10.1097\/HS9.0000000000000971","volume":"7","author":"M Katsin","year":"2023","unstructured":"Katsin M, Dormeshkin D, Meleshko A, Migas A, Dubovik S, Konoplya N. CAR-T cell therapy for classical Hodgkin lymphoma. Hemasphere. 2023;7(12):e971.","journal-title":"Hemasphere"},{"issue":"6","key":"13400_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.hoc.2023.05.017","volume":"37","author":"IN Muhsen","year":"2023","unstructured":"Muhsen IN, Hill LC, Ramos CA. Chimeric antigen receptor T cells in Hodgkin and T-cell lymphomas. Hematol Oncol Clin North Am. 2023;37(6):1107\u201324.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"13400_CR12","doi-asserted-by":"publisher","first-page":"e869","DOI":"10.1097\/HS9.0000000000000869","volume":"7","author":"AM Tun","year":"2023","unstructured":"Tun AM, Wang Y, Matin A, Inwards DJ, Habermann TM, Micallef I, Johnston PB, Porrata L, Paludo J, Bisneto JV, et al. Outcomes of patients with classic Hodgkin lymphoma who relapsed after autologous stem cell transplant. HemaSphere. 2023;7(4):e869.","journal-title":"HemaSphere"},{"key":"13400_CR13","doi-asserted-by":"crossref","unstructured":"Brudno JN, Natrakul DA, Karrs JX, Patel N, Maass-Moreno R, Ahlman MA, Mikkilineni L, Mann J, Stroncek DF, Highfill SL et al. Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase I trial. Blood Adv.\u00a02024;8(3):802\u201314.","DOI":"10.1182\/bloodadvances.2023011470"},{"issue":"8","key":"13400_CR14","doi-asserted-by":"publisher","first-page":"e006959","DOI":"10.1136\/jitc-2023-006959","volume":"11","author":"NP Tschernia","year":"2023","unstructured":"Tschernia NP, Heiling H, Deal AM, Cheng C, Babinec C, Gonzalez M, Morrison JK, Dittus C, Dotti G, Beaven AW, et al. Patient-reported outcomes in CD30-directed CAR-T cells against relapsed\/refractory CD30+ lymphomas. J Immunother Cancer. 2023;11(8):e006959.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"13400_CR15","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/bloodadvances.2021005385","volume":"6","author":"TJ Voorhees","year":"2022","unstructured":"Voorhees TJ, Zhao B, Oldan J, Hucks G, Khandani A, Dittus C, Smith J, Morrison JK, Cheng CJ, Ivanova A, et al. Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma. Blood Adv. 2022;6(4):1255\u201363.","journal-title":"Blood Adv"},{"key":"13400_CR16","doi-asserted-by":"publisher","first-page":"858021","DOI":"10.3389\/fimmu.2022.858021","volume":"13","author":"W Sang","year":"2022","unstructured":"Sang W, Wang X, Geng H, Li T, Li D, Zhang B, Zhou Y, Song X, Sun C, Yan D, et al. Anti-PD-1 therapy enhances the efficacy of CD30-directed chimeric antigen receptor T cell therapy in patients with relapsed\/refractory CD30+ lymphoma. Front Immunol. 2022;13:858021.","journal-title":"Front Immunol"},{"issue":"5","key":"13400_CR17","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"CM Wang","year":"2017","unstructured":"Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, Li X, Zhang YJ, Zhang WY, Chen MX, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23(5):1156\u201366.","journal-title":"Clin Cancer Res"},{"issue":"32","key":"13400_CR18","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38(32):3794\u2013804.","journal-title":"J Clin Oncol"},{"issue":"5","key":"13400_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","volume":"25","author":"ME Juweid","year":"2007","unstructured":"Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"13400_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/bloodadvances.2023011470","volume":"8","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Natrakul DA, Karrs J, Patel N, Maass-Moreno R, Ahlman MA, Mikkilineni L, Mann J, Stroncek DF, Highfill SL, et al. Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. Blood Adv. 2024;8(3):802\u201314.","journal-title":"Blood Adv"},{"issue":"9","key":"13400_CR21","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127(9):3462\u201371.","journal-title":"J Clin Invest"},{"issue":"1","key":"13400_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-022-00323-9","volume":"11","author":"P Zhang","year":"2022","unstructured":"Zhang P, Yang X, Cao Y, Wang J, Zhou M, Chen L, Wei J, Mao Z, Wang D, Xiao Y, et al. Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed\/refractory CD30(+) lymphoma. Exp Hematol Oncol. 2022;11(1):72.","journal-title":"Exp Hematol Oncol"},{"key":"13400_CR23","doi-asserted-by":"publisher","first-page":"1054314","DOI":"10.3389\/fonc.2022.1054314","volume":"12","author":"M Maranzano","year":"2022","unstructured":"Maranzano M, Mead M. The role of transplantation in Hodgkin lymphoma. Front Oncol. 2022;12:1054314.","journal-title":"Front Oncol"},{"issue":"3","key":"13400_CR24","first-page":"e57291","volume":"16","author":"A Goto","year":"2024","unstructured":"Goto A, Fujita C, Horiguchi H, Iyama S, Kobune M. Successful pregnancy and fetal outcomes following Brentuximab Vedotin for early relapsed classic Hodgkin lymphoma after autologous stem cell transplant. Cureus. 2024;16(3):e57291.","journal-title":"Cureus"},{"key":"13400_CR25","doi-asserted-by":"publisher","first-page":"1397053","DOI":"10.3389\/fonc.2024.1397053","volume":"14","author":"CJ Milrod","year":"2024","unstructured":"Milrod CJ, Pelcovits A, Ollila TA. Immune checkpoint inhibitors in advanced and relapsed\/refractory Hodgkin lymphoma: current applications and future prospects. Front Oncol. 2024;14:1397053.","journal-title":"Front Oncol"},{"issue":"1","key":"13400_CR26","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1182\/hematology.2023000450","volume":"2023","author":"NS Grover","year":"2023","unstructured":"Grover NS, Dittus C, Thakkar A, Beaven AW. The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure. Hematology Am Soc Hematol Educ Program. 2023;2023(1):510\u20138.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"13400_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/17843286.2018.1545373","volume":"75","author":"S Van Schandevyl","year":"2020","unstructured":"Van Schandevyl S, Kerre T. Chimeric antigen receptor T-cell therapy: design improvements and therapeutic strategies in cancer treatment. Acta Clin Belg. 2020;75(1):26\u201332.","journal-title":"Acta Clin Belg"},{"issue":"14","key":"13400_CR28","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1080\/10428194.2021.1957865","volume":"62","author":"WJ Plattel","year":"2021","unstructured":"Plattel WJ, Bergamasco A, Trinchese F, Gavini F, Bent-Ennakhil N, Zomas A, Castillon G, Arredondo-Bisono T, Cristarella T, Moride Y, et al. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2021;62(14):3320\u201332.","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"13400_CR29","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1182\/bloodadvances.2024013743","volume":"8","author":"N Epperla","year":"2024","unstructured":"Epperla N, Huang Y, Cashen AF, Vaughn JL, Hanel W, Badar T, Barta SK, Caimi PF, Sethi TK, Reddy N, et al. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Adv. 2024;8(21):5458\u201366.","journal-title":"Blood Adv"},{"issue":"6","key":"13400_CR30","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/j.clml.2024.02.007","volume":"24","author":"S Yamshon","year":"2024","unstructured":"Yamshon S, Gribbin C, Alhomoud M, Chokr N, Chen Z, Demetres M, Pasciolla M, Leonard J, Shore T, Martin P. Safety and toxicity profiles of CAR T cell therapy in non-Hodgkin lymphoma: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2024;24(6):e235-e256 e232.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13400-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13400-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13400-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T15:50:26Z","timestamp":1736869826000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13400-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13400"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13400-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"1 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}